Joshua P. FairbankMr. Fairbank leads the investment and finance team at Orchard. He is the cofounder of several healthcare and medical companies.
He is a co-founder and original director of Akebia Therapeutics (NASDAQ: AKBA). Founding Akebia he played a key role in all aspects from writing the business plan and hiring management to negotiating the acquisition of the assets from Procter & Gamble. Akebia raised $100 million in venture funding and another $100 million from its IPO. The company has advanced from early animal data to late stage human trials.
Founding Nymirum he built and implemented a non-dilutive business and financing model to enable the development of a novel drug discovery technology. He served as president and chairman at Nymirum, overseeing operations, finance, and business development as well as directing the computational component of the company's platform.
He actively works with the boards of other Orchard portfolio companies.
Prior to working in venture capital Fairbank spent a decade in investment banking and asset management. He began his financial career at Frank Russell, one of the original major fund of funds and fund advisors. He later founded an investment office at Raymond James that focused on private placements and working with large family investors.
J.P. received his MBA from the University of Chicago Booth School of Business and his bachelor's degree from Connecticut College with a double major in Economics and Government.
Michael E. Pape
A 25-year veteran of large pharmaceutical and startup life science companies, Dr Pape engages with portfolio companies in different capacities ranging from board director to scientific director.
At Upjohn and Parke-Davis/Warner-Lambert (now Pfizer) he was instrumental in the success of numerous cardiovascular drug discovery and development programs including Lipitor. Since Lipitor Mike has found similar success as an entrepreneur. In 1998 he co-founded Esperion Therapeutics. He held a variety of executive positions and was involved in nearly all aspects of building Esperion, from its startup to its acquisition by Pfizer for $1.3 billion in 2004. At Nymirum he again served in a broad capacity as CEO and CSO while as a co-founder of Akebia served as a board director and drug development advisor.
He has served as a board member of MichBio the state-wide organization promoting life sciences. He has also been an advisor or investor in numerous medical startup companies. He currently serves on the External Advisory Board for the Purdue Research Foundation Emerging Innovations Fund.
In addition to his company efforts, Mike lectures in a variety of biochemistry courses at the University of Michigan and has published dozens of biochemistry articles describing gene expression and drug activities in heart disease, diabetes, and obesity. Mike’s entrepreneurial achievements have led to his inclusion in the book How They Did It: Billion Dollar Insights from the Heart of America and being named recipient of the 2012 Distinguished Alumni Award in Entrepreneurship from the University of Chicago Booth School of Business.
Mike received his bachelor's degree in Microbiology from the University of Michigan, Ph.D. in Biochemistry from Purdue University, and MBA from the University of Chicago, Booth School of Business.